MedTrace Logo

A Trial of SHR-A1921 for Injection in Subjects With Advanced Solid Tumors

NCT05594875 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2024-06-25

No results posted yet for this study

Summary

The study is being conducted to evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of SHR-1921.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

SHR-1921

Subject will receive a single dose of SHR-1921 at dose level 1/2/3 on Day of each cycles

Sponsors & Collaborators

  • Atridia Pty Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2024-04-24
Completion
2024-04-24

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05594875 on ClinicalTrials.gov